VTRS

N/A

Viatris Inc.

Healthcare · Rank #486 · Analyzed Oct 18, 2026

$18.66

Current Price

⚠️ Unverified — fails data-quality checks

This ticker did not clear our Definition of Done, so its valuation is shown for transparency but should not be trusted:

• Intrinsic value not computed
• Insufficient data to rate
• <2 valuation methods computed

$0.00

Intrinsic Value

+158.8%

Upside/Downside

0/10

Score

0.8/5

Quality

Analysis Summary

Valuation Consensus1/1 methods agree

Quality Score0.8/5.0

Framework RatingINSUFFICIENT DATA

Price vs Intrinsic ValueUndervalued by 158.8%

Fair Value Range

Low$28.97

Base (IV)$0.00

High$72.42

Entry Points

Conservative$20.28

Moderate$28.97

Aggressive$33.80

⚠️ Warnings

Biotech/pharma: negative margins from R&D — using forward estimates
Insufficient data: fewer than 2 valuation methods

Quality & Moat Breakdown

Return on Equity-2.8% → 0/1.0

Debt LevelD/E 96 → 0/1.0

Revenue QualityGrowth 1.9%, margin Δ-7.7% +recovery → 0.5/1.0

Moat Strength2.0/5 → 0/1.0

Profit Margins-2.8% → 0.25/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.